Zentek air filters maintain efficacy after 20 months

GUELPH, ON - Zentek Ltd. (NASDAQ:ZTEK)(TSXV:ZEN), a $94 million market cap company specializing in intellectual property technology development and commercialization, recently announced that its ZenGUARD™ Enhanced Air Filters have retained viral filtration efficiency (VFE) after 20 months of aging. This result is crucial for compliance with medical device standards, as the filters are set to be sold as a Class I medical device. According to InvestingPro data, the stock has seen significant pressure recently, down 6% in the past week.

The tests conducted by LMS Technologies, Inc. showed that the aged filters had a VFE of 38.1%, closely matching the original performance of 37.7%. Additionally, a shedding test revealed that the ZenGUARD™ coating adheres well to the filter substrate over time, with particle counts after filtration remaining statistically consistent with background levels.

These findings allow Zentek to label the ZenGUARD™ Enhanced Air Filters with a 20-month expiry date from the date of manufacture. The company is finalizing all necessary documentation to support the manufacture and sale of these filters under its medical device establishment licence (MDEL), in accordance with Canadian Medical Device Regulations and the ISO 13485:2016 Quality Management System for medical devices. While advancing its product development, the company faces financial challenges with a gross profit margin of -806% and revenue of just $0.04 million in the last twelve months.

CEO Greg Fenton expressed satisfaction with the progress towards commercialization, emphasizing that the test results confirm the filters as an effective and safe solution for reducing the transmission of infectious bioaerosols up to the expiry date.

Zentek is known for its patented ZenGUARD™ technology, which aims to enhance bacterial and viral filtration efficiency in surgical masks and HVAC filters. The company’s production facility is located in Guelph, Ontario, and it also holds a global exclusive license for an aptamer-based platform technology developed by McMaster University. InvestingPro analysis identifies Zentek as a niche player in its industry, with over 10 additional key insights available to subscribers, including detailed financial health metrics and growth prospects.

The information for this article is based on a press release statement.

In other recent news, Zentek Ltd. has announced significant developments in its operations. Zentek’s subsidiary, Albany Graphite Corporation, achieved a graphite purity level of 99.9991% using a pilot-scale fluidized bed reactor. This ultra-high purity graphite is being evaluated for its suitability in lithium-ion battery anodes and potential nuclear industry applications. The purification process will undergo further optimization and analysis to identify any impurities, aligning with the rising demand for high-purity graphite in North America’s battery supply chain.

Additionally, Zentek has entered into a strategic partnership with Al-Ramez International Group, facilitated by Saudi Excellence Holding Company. This collaboration aims to foster the innovation and commercialization of advanced technologies in Saudi Arabia and the broader Middle East and North Africa region. The agreement includes plans for a graphene production facility in Saudi Arabia and a research center for aptamer technology in conjunction with a Saudi university. Zentek’s CEO, Greg Fenton, noted that this partnership aligns with the Saudi Green Initiative Vision 2030, highlighting the potential for technological investments to reduce the region’s carbon footprint. These recent developments mark a significant step for Zentek in expanding its international presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.